Displaying 1 - 15 of 15 tests
BRCA1 Mutation & Del/Dup Analysis

This test is performed by sequencing the entire BRCA1 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. This test maybe ordered separately or in combination with BRCA2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
BRCA1/2 Mutation & Del/Dup Analysis

This test is performed by sequencing the entire BRCA1 and BRCA2 genes using massive parallel sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Tests for BRCA1 or BRCA2 may be ordered separately. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
BRCA2 Mutation & Del/Dup Analysis

This test is performed by sequencing the entire BRCA2 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. This test maybe ordered separately or in combination with BRCA1. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
EGFR T790M Germline Mutation Analysis

Bidirectional sequence analysis of EGFR exon 20 in peripheral blood for detection of T790M germline mutation. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
EPCAM Mutation & Del/Dup Analysis

This test is performed by sequencing the entire EPCAM gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Testing is also available in the Lynch Syndrome panel which includes EPCAM, MLH1, MSH2, MSH6, and PMS2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
Hereditary Cancer Comprehensive Panel

Next-gen sequencing of all coding regions and intron-exon boundaries is performed concurrently for the following 73 genes: AKT1, APC, ATM, ATR, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CEBPA, CHEK1, CHEK2, CTNNA1, EPCAM, ETV6, FAM175A, GALNT12, GATA2, GEN1, GREM1, HOXB13, KLLN, MEN1, MLH1, MRE11A, MSH2, MSH6, MUTYH, MYH1, MYH2, MYH3, MYH4, MYH6, MYH7, MYH8, MYH9, MYH10, MYH11, MYH13, MYH14, MYH15, NBN, NTRK1, PALB2, PIK3CA, PMS2, POLD1, POLE, PPM1D, PRSS1, PTEN, RAD50, RAD51, RAD51C, RAD51D, RET, RUNX1, SDHB, SDHC, SDHD, SMAD4, STK11, TERC, TERT, TP53, TP53BP1, VHL, WT1, and XRCC2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
Hereditary Cancer Susceptibility for Pediatrics

The Hereditary Cancer Susceptibility for Pediatrics panel is a sequencing based assay that can detect mutations in the entire coding region of the following genes listed. ALK, APC, BRCA1, BRCA2, CDH1, KRAS, MSH2, MSH6, NF1, NF2, NRAS, PALB2, PMS2, PTCH1, RB1, RET, RUNX1, SDHA, SDHB, TP53, and VHL. Note: Parent and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
Hereditary DNA Repair Panel for Prostate Cancer

The Hereditary DNA Repair Panel for Prostate Cancer is a sequencing based assay that can detect mutations in the entire coding region of the following genes listed. ATM, ATR, BAP1, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, FAM175A, GEN1, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, and XRCC2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
HOXB13 Genotyping

This test is performed on a patient's blood specimen to look for germline genetic variants. The method is bi-directional sequencing of exons 1 and 2 of the HOXB13 gene for detection of the G84E mutation and other variants of significance to prostate cancer risk. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
Inherited Bone Marrow Failure Panel

The Inherited Bone Marrow Failure Panel consists of next-gen sequencing of all coding regions of the following 58 genes, shown grouped by categories of gene function or primary associated disease. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received. Fanconi Anemia: BRCA2 (FANCD1), BRIP1 (FANCJ), ERCC4 (FANCQ), FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, PALB2 (FANCN), RAD51C (FANCO), SLX4 (FANCP), XRCC2. Ribosome diseases: RPL5, RPL11, RPL15, RPL26, RPL35A, RPS7, RPS10, RPS17, RPS19, RPS24, RPS26. Telomere diseases: ACD (TPP1), CTC1, DKC1, NHP2 (NOLA2), NOP10 (NOLA3), POT1, RTEL1, TERC, TERF1 (TRF1), TERF2 (TRF2), TERF2IP (RAP1), TERT, TERT Promoter, TINF2, WRAP53. Acute myeloid leukemia (AML): CEBPA, DDX41, ETV6, RUNX1, SRP72. Severe congenital neutropenia (SCN): CSF3R, ELANE, G6PC3, GFI1, HAX1, WAS. Others: GATA1, GATA2, MPL, SBDS, THPO.

Molecular
Lynch Syndrome

This test is performed by sequencing the entire EPCAM, MLH1, MSH2, MSH6 and PMS2 genes using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Testing may be ordered for individual genes. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
MLH1 Mutation & Del/Dup Analysis

This test is performed by sequencing the entire MLH1 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Testing is also available in the Lynch Syndrome panel which includes EPCAM, MLH1, MSH2, MSH6, and PMS2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
MSH2 Mutation & Del/Dup Analysis

This test is performed by sequencing the entire MSH2 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Testing is also available in the Lynch Syndrome panel which includes EPCAM, MLH1, MSH2, MSH6, and PMS2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
MSH6 Mutation & Del/Dup Analysis

This test is performed by sequencing the entire MSH6 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Testing is also available in the Lynch Syndrome panel which includes EPCAM, MLH1, MSH2, MSH6, and PMS2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular
PMS2 Mutation & Del/Dup Analysis

This test is performed by sequencing the entire PMS2 gene using next-gen sequencing complemented by conventional Sanger sequencing or other molecular methodologies to detect point mutations, small insertions/deletions, and large deletions/duplications. Testing is also available in the Lynch Syndrome panel which includes EPCAM, MLH1, MSH2, MSH6, and PMS2. Note: Patient and physician or genetic counselor signatures on the NeoGenomics Consent for Hereditary Cancer Genetic Testing form are required. Testing will be put on hold until signatures are received.

Molecular